Dear Reader,
We have identified several healthtech stocks which are expected to go “Ex-Dividend” starting today, June 14th.
If you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment.
Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend.
So please keep this in mind.
Below is our latest Dividend Report:
Conmed
Symbol: CNMD
Recent Price: $96.29
Average Analyst Price Target: $157.50 (63.57%)
Market Cap: $2.84B
Expected Ex-Dividend Date: Jun 14 2022
Expected Payment Date: Jul 05 2022
Expected Dividend & Yield: 0.78%
Recent Analyst Action: Rick Wise, analyst at Stifel Nicolaus, reiterates coverage on Conmed (CNMD) in the Healthcare sector with a Buy rating and a price target of $ 160 (1 month ago).
TipRanks.com also reports that Conmed currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $157.50 . The target pricing ranges from a high forecast of $160.00 down to a low forecast of $155.00. Conmed (CNMD)’s last closing price was $$96.29 which would put the average price target at 63.57% upside.Here are 3rd party ratings for CNMD:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Sell, Bottom 12% (222 out of 253)
--------------------------------------------------------------------------
Gilead Sciences
Symbol: GILD
Recent Price: $58.59
Average Analyst Price Target: $70.18 (19.78%)
Market Cap: $73.49B
Expected Ex-Dividend Date: Jun 14 2022
Expected Payment Date: Jun 29 2022
Expected Dividend & Yield: 4.74%
Recent Analyst Action: Evan Seigerman, analyst at BMO Capital, reiterates coverage on Gilead Sciences (GILD) in the Healthcare sector with a Hold rating and a price target of $ 63 (1 week ago).
TipRanks.com also reports that Gilead Sciences currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $70.18 . The target pricing ranges from a high forecast of $84.00 down to a low forecast of $63.00. Gilead Sciences (GILD)’s last closing price was $$58.59 which would put the average price target at 19.78% upside.Here are 3rd party ratings for GILD:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 41% (104 out of 253)
--------------------------------------------------------------------------
Merck & Company
Symbol: MRK
Recent Price: $84.52
Average Analyst Price Target: $98.20 (16.19%)
Market Cap: $213.73B
Expected Ex-Dividend Date: Jun 14 2022
Expected Payment Date: Jul 08 2022
Expected Dividend & Yield: 3.12%
Recent Analyst Action: Mara Goldstein, analyst at Mizuho Securities, reiterates coverage on Merck & Company (MRK) in the Healthcare sector with a Buy rating and a price target of $ 100 (1 week ago).
TipRanks.com also reports that Merck & Company currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $98.20 . The target pricing ranges from a high forecast of $107.00 down to a low forecast of $87.00. Merck & Company (MRK)’s last closing price was $$84.52 which would put the average price target at 16.19% upside.Here are 3rd party ratings for MRK:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Bottom 29% (180 out of 253)
--------------------------------------------------------------------------
Thermo Fisher
Symbol: TMO
Recent Price: $509.90
Average Analyst Price Target: $641.67 (25.84%)
Market Cap: $199.61B
Expected Ex-Dividend Date: Jun 14 2022
Expected Payment Date: Jul 15 2022
Expected Dividend & Yield: 0.21%
Recent Analyst Action: David Toung, analyst at Argus Research, reiterates coverage on Thermo Fisher (TMO) in the Healthcare sector with a Buy rating and a price target of $ 640 (2 weeks ago).
TipRanks.com also reports that Thermo Fisher currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $641.67 . The target pricing ranges from a high forecast of $711.00 down to a low forecast of $525.00. Thermo Fisher (TMO)’s last closing price was $$509.90 which would put the average price target at 25.84% upside.Here are 3rd party ratings for TMO:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 29% (174 out of 251)
--------------------------------------------------------------------------
HCA Healthcare
Symbol: HCA
Recent Price: $184.47
Average Analyst Price Target: $254.06 (37.72%)
Market Cap: $54.51B
Expected Ex-Dividend Date: Jun 15 2022
Expected Payment Date: Jun 30 2022
Expected Dividend & Yield: 1.06%
Recent Analyst Action: Lance Wilkes, analyst at Bernstein, reiterates coverage on HCA Healthcare (HCA) in the Healthcare sector with a Buy rating and a price target of $ 271 (2 weeks ago).
TipRanks.com also reports that HCA Healthcare currently has 16 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $254.06 . The target pricing ranges from a high forecast of $275.00 down to a low forecast of $227.00. HCA Healthcare (HCA)’s last closing price was $$184.47 which would put the average price target at 37.72% upside.Here are 3rd party ratings for HCA:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 27% (185 out of 253)
--------------------------------------------------------------------------
And there you have it...
Keep in mind, if you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment.
Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend.
If you have questions about specific dividends, you should consult with your financial advisor or visit Investor.gov for more information.
Sincerely,
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
